Cargando…

The Positive Effects of One-Hour Intravenous Administration of Bortezomib on Peripheral Neuropathy in Multiple Myeloma Patients

Bortezomib-induced peripheral neuropathy (BiPN) in multiple myeloma (MM) patients is a common and serious side effect. Currently, it has been reported that subcutaneous (SC) administration of bortezomib decreases the incidence of BiPN as compared to standard intravenous (IV) bolus injection without...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jung, Joo Young, Kim, Ho Young, Han, Boram, Choi, Dae Ro, Zang, Dae Young, Kim, Hyo Jung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065765/ https://www.ncbi.nlm.nih.gov/pubmed/24995276 http://dx.doi.org/10.1155/2014/237698

Ejemplares similares

Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study
por: Garcia, M Kay, et al.
Publicado: (2014)

Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy
por: Minarik, Jiri, et al.
Publicado: (2015)

A Phase II Study to Evaluate the Efficacy of Ramosetron, Aprepitant, and Dexamethasone in Preventing Cisplatin-Induced Nausea and Vomiting in Chemotherapy-Naïve Cancer Patients
por: Jang, Geundoo, et al.
Publicado: (2013)

Bortezomib-induced painful neuropathy in patients with multiple myeloma
por: Bilińska, Małgorzata, et al.
Publicado: (2013)

Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy
por: Yamamoto, Shota, et al.
Publicado: (2021)

The protective effects of lafutidine for bortezomib induced peripheral neuropathy
por: Tsukaguchi, Machiko, et al.
Publicado: (2013)

Acupuncture for Bortezomib-Induced Peripheral Neuropathy: Not Just for Pain
por: Zhi, W. Iris, et al.
Publicado: (2018)

A phase II study of chemotherapy in combination with telomerase peptide vaccine (GV1001) as second-line treatment in patients with metastatic colorectal cancer
por: Kim, Sejin, et al.
Publicado: (2022)

Clinicopathologic Significance of VHL Gene Alteration in Clear-Cell Renal Cell Carcinoma: An Updated Meta-Analysis and Review
por: Kim, Hyeong Su, et al.
Publicado: (2018)

Pathological and Prognostic Impacts of FGFR2 Overexpression in Gastric Cancer: A Meta-Analysis
por: Kim, Hyeong Su, et al.
Publicado: (2019)

Bortezomib-related neuropathy may mask CNS relapse in multiple myeloma: A call for diligence
por: Abid, Muhammad Bilal, et al.
Publicado: (2016)

Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy
por: Jeter, Ashley, et al.
Publicado: (2012)

Bortezomib/lenalidomide: Interstitial pneumonitis and peripheral neuropathy: case report
Publicado: (2020)

Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data
por: Maschio, Marta, et al.
Publicado: (2018)

Complete Atrioventricular Block Secondary to Bortezomib Use in Multiple Myeloma
por: Lee, Won-Seop, et al.
Publicado: (2011)

Dose Adjustment Helps Obtain Better Outcomes in Multiple Myeloma Patients with Bortezomib, Melphalan, and Prednisolone (VMP) Treatment
por: Cho, Su-Hee, et al.
Publicado: (2019)

Acupuncture Treatment for Bortezomib-Induced Peripheral Neuropathy: A Case Report
por: Bao, Ting, et al.
Publicado: (2011)

Pathogenic role of delta 2 tubulin in bortezomib-induced peripheral neuropathy
por: Pero, Maria Elena, et al.
Publicado: (2021)

Bortezomib induced peripheral neuropathy and single nucleotide polymorphisms in PKNOX1
por: Zhou, Xiang, et al.
Publicado: (2023)

Single-cell analysis of multiple myelomas refines the molecular features of bortezomib treatment responsiveness
por: Jung, Seung-Hyun, et al.
Publicado: (2022)

Novel genes exhibiting DNA methylation alterations in Korean patients with chronic lymphocytic leukaemia: a methyl-CpG-binding domain sequencing study
por: Kim, Miyoung, et al.
Publicado: (2020)

Poor prognostic significance of Mycobacterium tuberculosis infection during bortezomib-containing chemotherapy in patients with multiple myeloma
por: Ahn, Jae-Sook, et al.
Publicado: (2013)

Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
por: Lee, Se Ryeon, et al.
Publicado: (2019)

Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma
por: Ahn, Jae-Sook, et al.
Publicado: (2014)

A Case of Drug-Induced Hepatitis due to Bortezomib in Multiple Myeloma
por: Kim, Youngwoon, et al.
Publicado: (2012)

Phytohemagglutinin-induced IL2 mRNA in whole blood can predict bortezomib-induced peripheral neuropathy for multiple myeloma patients
por: Watanabe, T, et al.
Publicado: (2013)

Bortezomib-induced aerobic glycolysis contributes to chemotherapy-induced painful peripheral neuropathy
por: Ludman, Taylor, et al.
Publicado: (2019)

Specific Attenuation of Purinergic Signaling during Bortezomib-Induced Peripheral Neuropathy In Vitro
por: Holzer, Anna-Katharina, et al.
Publicado: (2022)

The risk factors for herpes zoster in bortezomib treatment in patients with multiple myeloma
por: Yi, Yang-Seon, et al.
Publicado: (2010)

Neuropathic pain in hereditary peripheral neuropathy
por: Jeong, Na Young, et al.
Publicado: (2013)

The Clinical Utility of FDG PET-CT in Evaluation of Bone Marrow Involvement by Lymphoma
por: Kim, Ho Young, et al.
Publicado: (2015)

Pyridoxine induced neuropathy by subcutaneous administration in dogs
por: Chung, Jin-Young, et al.
Publicado: (2008)

Real-world evidence of levofloxacin prophylaxis in elderly patients with newly diagnosed multiple myeloma who received bortezomib, melphalan, and prednisone regimen
por: Kim, Su-In, et al.
Publicado: (2022)

Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis
por: Sidana, Surbhi, et al.
Publicado: (2017)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma
por: Lee, Sang Wu, et al.
Publicado: (2021)

Changes in Osteoblastic Activity in Patient Who Received Bortezomib as Second Line Treatment for Plasma Cell Myeloma: A Prospective Multicenter Study
por: Eom, Ki-Seong, et al.
Publicado: (2014)

Bortezomib-Induced Painful Peripheral Neuropathy: An Electrophysiological, Behavioral, Morphological and Mechanistic Study in the Mouse
por: Carozzi, Valentina A., et al.
Publicado: (2013)

A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer
por: Kim, Jung Han, et al.
Publicado: (2015)

Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study
por: Jung, Jongheon, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8t6srh2t5pvfsk4a8iugjs253u